Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Passes Below 200 Day Moving Average – Should You Sell?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $14.17 and traded as low as $6.07. Arcturus Therapeutics shares last traded at $6.25, with a volume of 749,736 shares traded.

Analysts Set New Price Targets

A number of research firms have recently commented on ARCT. Leerink Partners cut their price objective on Arcturus Therapeutics from $63.00 to $54.00 and set an “outperform” rating on the stock in a report on Friday, August 22nd. Guggenheim downgraded shares of Arcturus Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 22nd. Citigroup cut their target price on shares of Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a research note on Thursday, November 13th. Zacks Research lowered shares of Arcturus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, October 24th. Finally, Wall Street Zen upgraded Arcturus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Seven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $36.00.

Arcturus Therapeutics Price Performance

The company has a market cap of $177.56 million, a price-to-earnings ratio of -2.54 and a beta of 2.10. The stock has a 50-day moving average price of $13.24 and a 200 day moving average price of $14.17.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($1.09) by $0.60. The business had revenue of $17.15 million for the quarter, compared to analysts’ expectations of $17.47 million. Arcturus Therapeutics had a negative net margin of 68.35% and a negative return on equity of 28.68%. Sell-side analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

A number of hedge funds have recently made changes to their positions in the business. US Bancorp DE boosted its position in shares of Arcturus Therapeutics by 218.9% in the first quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 2,329 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new stake in Arcturus Therapeutics in the 1st quarter worth about $161,000. Vanguard Group Inc. boosted its holdings in Arcturus Therapeutics by 3.8% in the 1st quarter. Vanguard Group Inc. now owns 1,748,928 shares of the biotechnology company’s stock valued at $18,521,000 after purchasing an additional 64,367 shares during the period. Deutsche Bank AG grew its position in shares of Arcturus Therapeutics by 10.1% during the 1st quarter. Deutsche Bank AG now owns 27,280 shares of the biotechnology company’s stock worth $289,000 after purchasing an additional 2,512 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Arcturus Therapeutics by 9.2% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 14,693 shares of the biotechnology company’s stock worth $156,000 after purchasing an additional 1,232 shares in the last quarter. 94.54% of the stock is owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.